ViewRay Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de ViewRay.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.1%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como ViewRay no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

OTCPK:VRAY.Q - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2023	106	-110	-117	-113	N/A
12/31/2022	102	-107	-96	-92	N/A
9/30/2022	88	-107	-79	-74	N/A
6/30/2022	81	-106	-80	-76	N/A
3/31/2022	73	-109	-71	-68	N/A
12/31/2021	70	-110	-64	-62	N/A
9/30/2021	68	-109	-65	-60	N/A
6/30/2021	59	-112	-64	-59	N/A
3/31/2021	58	-107	-61	-55	N/A
12/31/2020	57	-108	-70	-63	N/A
9/30/2020	55	-117	-65	-63	N/A
6/30/2020	66	-110	-80	-75	N/A
3/31/2020	82	-114	-98	-91	N/A
12/31/2019	88	-120	-87	-80	N/A
9/30/2019	92	-102	-130	-121	N/A
6/30/2019	89	-114	-129	-123	N/A
3/31/2019	75	-105	-113	-108	N/A
12/31/2018	81	-79	-126	-122	N/A
9/30/2018	80	-87	-108	-104	N/A
6/30/2018	75	-65	-99	-95	N/A
3/31/2018	59	-52	-98	-96	N/A
12/31/2017	34	-72	-72	-70	N/A
9/30/2017	30	-59	-45	-44	N/A
6/30/2017	18	-61	-34	-31	N/A
3/31/2017	18	-65	-33	-30	N/A
12/31/2016	22	-51	N/A	-28	N/A
9/30/2016	11	-54	N/A	-37	N/A
6/30/2016	16	-50	N/A	-40	N/A
3/31/2016	16	-50	N/A	-41	N/A
12/31/2015	10	-45	N/A	-40	N/A
9/30/2015	6	-41	N/A	-32	N/A
6/30/2015	4	-38	N/A	-27	N/A
3/31/2015	5	-34	N/A	-27	N/A
12/31/2014	6	-34	N/A	-27	N/A
9/30/2014	8	-32	N/A	-32	N/A
12/31/2013	3	-28	N/A	-25	N/A
12/31/2012	2	-25	N/A	-19	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de VRAY.Q es superior a la tasa de ahorro (2.2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de VRAY.Q crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de VRAY.Q crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de VRAY.Q crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de VRAY.Q crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de VRAY.Q se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

ViewRay Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 16%

Consensus revenue estimates decrease by 12%, EPS upgraded

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

Viewray, Inc. Updates Earnings Guidance for the Year 2022

Consensus estimates of losses per share improve by 11%

Price target decreased to US$7.43

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus revenue estimates decrease by 16%

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% Lower

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$117k worth of stock

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer center

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay's MRI-guided radiation therapy gets approval in China

ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare System

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

ViewRay: Insider Buying In This $3 Stock

Consensus estimates of losses per share improve by 11%

President recently bought US$400k worth of stock

Price target decreased to US$7.43

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$96k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)

Chief Financial Officer recently bought US$213k worth of stock

Price target increased to US$8.03

Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

ViewRay, Inc. 2021 Q1 - Results - Earnings Call Presentation

Price target increased to US$6.32

Chief Operating Officer has left the company

ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021

Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019)

Revenue beats expectations

Read This Before Selling ViewRay, Inc. (NASDAQ:VRAY) Shares

ViewRay, Inc. to Report Q4, 2020 Results on Mar 04, 2021

ViewRay, Inc. Announces Retirement of D. Keith Grossman from Board of Directors

Viewray, Inc. Appoints Phil Spencer to Its Board of Directors

Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian Linac

The Henry Ford Cancer Institute Installs Its Second Viewray Mridian® Linac

How Many ViewRay, Inc. (NASDAQ:VRAY) Shares Do Institutions Own?